Bio-Thera Solutions’ BAT1806 receives China NMPA approval
Bio-Thera Solutions has received approval for the biosimilar of Actemra (tocilizumab), BAT1806, from the National Medical Products Administration (NMPA) of China.
Bio-Thera Solutions has received approval for the biosimilar of Actemra (tocilizumab), BAT1806, from the National Medical Products Administration (NMPA) of China.
Santhera Pharmaceuticals and ReveraGen BioPharma have announced the acceptance of vamorolone’s new drug application (NDA) for filing by the US Food and Drug Administration (FDA) to treat Duchenne muscular dystrophy (DMD).
Stealth BioTherapeutics has received Orphan Drug Designation from the US Food and Drug Administration (FDA) Office of Orphan Products Development for elamipretide to treat Duchenne muscular dystrophy (DMD) patients.